Drug General Information |
Drug ID |
D0KB2R
|
Former ID |
DNC013962
|
Drug Name |
N-(1-Methyl-1H-indol-2-ylmethyl)-N-phenylamine
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C16H16N2
|
Canonical SMILES |
CN1C2=CC=CC=C2C=C1CNC3=CC=CC=C3
|
InChI |
1S/C16H16N2/c1-18-15(11-13-7-5-6-10-16(13)18)12-17-14-8-3-2-4-9-14/h2-11,17H,12H2,1H3
|
InChIKey |
HTRZQOWAQJHGBR-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Amine oxidase [flavin-containing] A |
Target Info |
Inhibitor |
[1]
|
BioCyc Pathway
|
Superpathway of tryptophan utilization
|
Dopamine degradation
|
Putrescine degradation III
|
Noradrenaline and adrenaline degradation
|
Serotonin degradation
|
Superpathway of melatonin degradation
|
Melatonin degradation II
|
KEGG Pathway
|
Glycine, serine and threonine metabolism
|
Arginine and proline metabolism
|
Histidine metabolism
|
Tyrosine metabolism
|
Phenylalanine metabolism
|
Tryptophan metabolism
|
Drug metabolism - cytochrome P450
|
Metabolic pathways
|
Serotonergic synapse
|
Dopaminergic synapse
|
Cocaine addiction
|
Amphetamine addiction
|
Alcoholism
|
NetPath Pathway
|
IL4 Signaling Pathway
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesis
|
5-Hydroxytryptamine degredation
|
Dopamine receptor mediated signaling pathway
|
PathWhiz Pathway
|
Histidine Metabolism
|
Tyrosine Metabolism
|
Glycine and Serine Metabolism
|
Reactome
|
Norepinephrine Neurotransmitter Release Cycle
|
WikiPathways
|
SIDS Susceptibility Pathways
|
Biogenic Amine Synthesis
|
Oxidative Stress
|
Dopamine metabolism
|
Phase 1 - Functionalization of compounds
|
Neurotransmitter Release Cycle
|
Neurotransmitter Clearance In The Synaptic Cleft
|
Serotonin Transporter Activity
|
References |
REF 1 | Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. Epub 2008 Oct 2.Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. |